-(1).png "Familial Chylomicronemia Syndrome Market")
Familial Chylomicronemia Syndrome Market
Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive metabolic disorder caused by a mutation in lipoprotein lipase. Lipoprotein lipase is a digestive enzyme in the blood that helps the body break down chylomicrons. People with FCS are either unable to make lipoprotein lipase or have a broken form.
Familial Chylomicronemia Syndrome Market Insight (2022)
- The Familial Chylomicronemia Syndrome Market size in the 7MM was valued ~USD 15 million in 2022
- WAYLIVRA (volanesorsen), the only approved drug in Europe, covered the highest market size in the 7MM.
Familial Chylomicronemia Syndrome Epidemiology Insights (2022)
The Familial Chylomicronemia Syndrome Diagnosed prevalent cases in the 7MM were ~2K cases in 2022
Familial Chylomicronemia Syndrome Emerging Drugs and Key Companies
- Olezarsen: Ionis Pharmaceuticals
- ARO-APOC3: Arrowhead Pharmaceuticals, Inc., and others